市场见解

Medical Developments (ASX:MVP) share price falls on $13 million loss

Investors are selling their shares in the company after today’s announcement.
The post Medical Developments (ASX:MVP) share price falls on $13 million loss appeared first on The Motley Fool Australia. –

The Medical Developments International (ASX: MVP) share price is lower after the company released its full-year results for FY21.

At the time of writing, shares in the company are trading for $3.93 – down 2.48%. The ASX All Ordinaries Index (ASX: XAO), meanwhile, is 0.48% higher.

Let’s take a closer look at today’s announcement.

Medical Developments share price slumps despite 27% gross profit jump

Revenue increased 12.1% on the prior corresponding period (pcp) to $25.6 million and gross profit leaped 27.4% to $19.1 million.
A net profit after tax (NPAT) of $379,000 in FY20 turned into a $12.6 million loss for the period. This was driven mostly by a $9.6 million rise in administration expenses and a new $8.9 million impairment expense.
Net cash outflow from operating activities of $8.9 million.
Basic loss per share of 18.4 cents. In the pcp it was a gain of 0.58 cents per share.
No full-year dividend was paid, as was the case in FY20.

What happened in FY21 for Medical Developments

The first significant announcement of Medical Developments in FY21 was the announcement of its expansion into Europe. The Medical Developments share price jumped 14% on the news at the time. Chair David Williams called the news a “turning point” for the company.

In October, Medical Developments appointed Brent McGregor as CEO of the company. He previously worked for CSL Limited (ASX: CSL).

The company also acquired the distribution rights to its product in Australia in the financial year and implemented a capital raising scheme.

Medical Developments also said the COVID pandemic affected sales of its pain relief and respiratory products. This was because fewer people were out and about (and therefore getting injured) and there was less cold and flu in the community due to border restrictions.

What did management say?

McGregor gave the following comments on today’s results.

I am as confident as I was in November in the potential of MVP. Promising work has continued on our next generation product (“Selfie”) and we are beginning to think of other innovations to support strategic sales growth.

Finally, I acknowledge the resilience and commitment of the (now international) MVP team who have worked extraordinarily hard in a difficult and uncertain time to maintain the supply of our important products to patients.

What’s next for Medical Developments

Looking forward, Medical Developments anticipates “strong sales growth” in FY22. It says it will be driven by its expanding European presence and a “renewed focus” on the Australian market.

More updates will be provided at the October AGM.  Despite this outlook, the Medical Developments share price is slipping today.

Medical Developments share price snapshot

Over the past 12 months, the Medical Developments share price has decreased 34.2%. Year-to-date, it is down an even greater 40.8%.

Medical Developments has a market capitalisation of $287 million.

The post Medical Developments (ASX:MVP) share price falls on $13 million loss appeared first on The Motley Fool Australia.

Should you invest $1,000 in Medical Developments right now?

Before you consider Medical Developments, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Medical Developments wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Hansen Technologies (ASX:HSN) share price takes off on record FY21 results
APA Group (ASX:APA) share price plunges on flat earnings growth in FY21
SILK Laser (ASX:SLA) share price rockets 20% after beating FY21 guidance
Northern Star (ASX:NST) share price up after reporting 300% profit surge
Bravura Solutions (ASX:BVS) share price plunges 17% on FY21 earnings

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. and Medical Developments International Limited. The Motley Fool Australia owns shares of and has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!